voclosporin (Lupkynis) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Voclosporin, sold under the brand name Lupkynis, is a calcineurin inhibitor used as an immunosuppressant medication for the treatment of lupus nephritis. It is an analog of ciclosporin that has enhanced action against calcineurin and greater metabolic stability.   Wikipedia

Chemistry

  • SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
  • InChIKey: BICRTLVBTLFLRD-JDCIFRKPSA-N
  • Mol. Mass: 1214.65
  • ALogP: Missing data
  • ChEMBL Molecule:
    voclosporin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$48.4167 - $48.4168
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

isa247 | isa 247 | isa-247 | isatx247 | isa(tx)247 | lx211 | voclosporin

Organizations (19)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

COVID-19 (Phase 2)

Dry Eye Syndromes (Phase 2/Phase 3)

Glomerulosclerosis, Focal Segmental (Phase 2)

Keratoconjunctivitis Sicca (Phase 2/Phase 3)

Kidney Diseases (Phase 2)

Kidney Transplantation (Phase 3)

Lupus Nephritis (Phase 3)

Panuveitis (Phase 3)

Psoriasis (Phase 3)

Uveitis (Phase 3)

Uveitis, Anterior (Phase 3)

Uveitis, Intermediate (Phase 3)

Uveitis, Posterior (Phase 3)

Volunteers (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 23
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue